A novel in vivo Cerenkov luminescence image‐guided surgery on primary and metastatic colorectal cancer

2019 ◽  
Vol 13 (3) ◽  
Author(s):  
Zeyu Zhang ◽  
Yawei Qu ◽  
Yu Cao ◽  
Xiaojing Shi ◽  
Hongbo Guo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Image Guided Surgery ◽  
Guided Surgery ◽  
Image Guided

scholarly journals Novel bright-emission small-molecule NIR-II fluorophores for in vivo tumor imaging and image-guided surgery

2017 ◽  
Vol 8 (5) ◽  
pp. 3489-3493 ◽  
Author(s):  
Yao Sun ◽  
Mingmin Ding ◽  
Xiaodong Zeng ◽  
Yuling Xiao ◽  
Huaping Wu ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Small Molecule ◽  
Tumor Imaging ◽  
Image Guided Surgery ◽  
Guided Surgery ◽  
Image Guided ◽  
Bright Emission

This work presents the establishment of novel bright-emission small-molecule NIR-II fluorophores forin vivotumor imaging and NIR-II image-guided sentinel lymph node surgery.

Image-guided surgery for tumor agnostic detection of solid tumors using the pH-activated micellar imaging agent ONM-100.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3068-3068 ◽  
Author(s):  
Floris Jan Voskuil ◽  
Pieter Jan Steinkamp ◽  
Marjory Koller ◽  
Bert van der Vegt ◽  
Jan Johannes Doff ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Fluorescent Imaging ◽  
Activation Mechanism ◽  
Imaging Agent ◽  
Image Guided Surgery ◽  
Pharmacokinetic Data ◽  
Guided Surgery ◽  
Image Guided ◽  
Fluorescence Images

3068 Background: ONM-100, a micelle-based polymer imaging agent conjugated to indocyanine green (ICG) and with an exquisitely pH-sensitive binary activation mechanism, may be used for tumor detection. ONM-100 micelles dissociate in acidic environments resulting in activation of the fluorescent ICG tag. As nearly all solid cancer types are acidotic, ONM-100 has the potential to act as a broadly indicated tumor agnostic imaging agent. This first-in-human study investigates the safety and feasibility of ONM-100 as a tumor agnostic imaging agent for intra-operative fluorescent imaging of various solid tumors. Methods: ONM-100 was IV administered 24±8h prior to surgery in a dose escalation scheme (0.1-1.2mg/kg). Patients with histopathologically confirmed breast cancer (BC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC) and esophageal cancer (EC) were included. Blood was drawn to assess safety and pharmacokinetic data. Intra-operative fluorescence images were collected before and after tumor excision. Post-excision fluorescence images were obtained from serially sliced specimens and correlated with standard histopathological assessment. Results: 30 patients (11 BC, 13 HNSCC, 3 EC, 3 CRC) were enrolled. No ONM-100 related serious adverse events were observed and the agent was well-tolerated. A strong and sharply demarcated fluorescent signal was observed in all patients with vital tumor tissue (median CNR ranging 1.85-14.05) which correlated with tumor on final histopathology. HNSCC and superficially located BC as well as peritoneal metastasis could be clearly visualized in vivo during surgery. In four patients (BC and HNSCC), perioperatively, tumors otherwise unnoticed by the surgeons were detected on the margin or wound bed using fluorescence imaging. Additionally, two BC tumor lesions were detected that were missed by conventional pre-operative imaging and pathological assessment. Conclusions: ONM-100 appears to be safe and enables fluorescent visualization of tumors both in vivo and ex vivo. The first-in-human data demonstrate the feasibility for potential use of ONM-100 for image guided surgery, margin assessment and detection of occult disease. Clinical trial information: NTR 7085.

scholarly journals Pharmacokinetic and Biodistribution Assessment of a Near Infrared-Labeled PSMA-Specific Small Molecule in Tumor-Bearing Mice

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Joy L. Kovar ◽  
Lael L. Cheung ◽  
Melanie A. Simpson ◽  
D. Michael Olive
Keyword(s):  
Small Molecule ◽  
Near Infrared ◽  
Image Guided Surgery ◽  
Tumor Delineation ◽  
Guided Surgery ◽  
Image Guided ◽  
Tumor Bearing ◽  
Tissue Contrast

Prostate cancer is the most frequently diagnosed cancer in men and often requires surgery. Use of near infrared (NIR) technologies to perform image-guided surgery may improve accurate delineation of tumor margins. To facilitate preclinical testing of such outcomes, here we developed and characterized a PSMA-targeted small molecule, YC-27. IRDye 800CW was conjugated to YC-27 or an anti-PSMA antibody used for reference. Human 22Rv1, PC3M-LN4, and/or LNCaP prostate tumor cells were exposed to the labeled compounds.In vivotargeting and clearance properties were determined in tumor-bearing mice. Organs and tumors were excised and imaged to assess probe localization. YC-27 exhibited a dose dependent increase in signal upon binding. Binding specificity and internalization were visualized by microscopy.In vitroandin vivoblocking studies confirmed YC-27 specificity.In vivo, YC-27 showed good tumor delineation and tissue contrast at doses as low as 0.25 nmole. YC-27 was cleared via the kidneys but bound the proximal tubules of the renal cortex and epididymis. Since PSMA is also broadly expressed on the neovasculature of most tumors, we expect YC-27 will have clinical utility for image-guided surgery and tumor resections.

Quantification of True In Vivo (Application) Accuracy in Cranial Image-guided Surgery: Influence of Mode of Patient Registration

2006 ◽  
Vol 59 ◽  
pp. ONS-146-ONS-156 ◽  
Author(s):  
Christopher R. Mascott ◽  
Jean-Christophe Sol ◽  
Philippe Bousquet ◽  
Jacques Lagarrigue ◽  
Yves Lazorthes ◽  
...  
Keyword(s):  
Image Guided Surgery ◽  
Patient Registration ◽  
Guided Surgery ◽  
Image Guided

In vivo animal image-guided surgery by fluorescence imaging applied to nerve

2019 ◽  
Author(s):  
F. Fanjul-Vélez ◽  
A. M. Díaz-Martínez ◽  
E. Garro-Martínez ◽  
J. L. Arce-Diego
Keyword(s):  
Fluorescence Imaging ◽  
Image Guided Surgery ◽  
Guided Surgery ◽  
Image Guided ◽  
Animal Image
Sign in / Sign up

Export Citation Format

Share Document